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Abstract
Objective Cerebrospinal fluid (CSF) shunting can improve
symptoms of elderly patients' idiopathic normal pressure
hydrocephalus (iNPH). However, adjunctive means for
confirming the diagnosis remain unavailable. We have
previously reported the specific increase of leucine-rich
alpha-2-glycoprotein (LRG) in iNPH CSF, and the present
study investigates its potential clinical applications.
Methods We performed CSF tap test (TT) on 90 patients
(mean age 73.4 years) and shunting in 52 patients (mean
age 73.5 years), evaluating symptom improvement and
higher cerebral functions—mini-mental state examination
(MMSE) and Frontal Assessment Battery (FAB) before and
12 months after shunting. LRG and tau protein concen-
trations in TT CSF were simultaneously measured using
enzyme-linked immunosorbent assay. We then compared
the predictive value of these concentrations with TT results
regarding successful shunting outcomes.
Results Positive combinations of TT and LRG concentra-
tions of 67 ng/ml or higher, gave 81.6% sensitivity and
78.6% specificity. Therefore we used LRG (67 ng/ml) and
tau (200 pg/ml) cut-off values, dividing patients into four
groups. In group A (LRG≥67 ng/ml and tau<200 pg/ml)
31 of 34 patients (91.2%) had a positive TT and all operated
22 patients were shunt responders. Dementia MMSE and
FAB scores in them increased from a baseline of 22.05(SE
±0.96) to 25.65 (±0.85) and 11.38 (±0.68) to 13.08 (±0.57)
respectively. In group B, (LRG≥67 ng/ml and tau≥200 pg/
ml), the mean MMSE score increased from 17.62 (±2.03) to
21.62 (±1.96), and the FAB decreased slightly from 9.25
(±1.15) to 10.5 (±1.59), without improvement beyond the
range of dementia. In group C, (LRG<67 ng/ml, tau<
200 pg/ml), the mean MMSE score improved from 22.06
(±1.25) to 24.29 (±1.23) and the FAB score improved
slightly from 12.0 (±0.72) to 12.87 (±0.72). Finally, in
group D, (LRG<67 ng/ml, tau≥200 pg/ml), there was
almost no improvement in MMSE score
Conclusions A combination of positive TT and biomarkers
quantification such as LRG and tau protein, can reliably
predict shunting outcome in iNPH patients.
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Introduction
The diagnosis of idiopathic normal pressure hydrocephalus
(iNPH) in elderly patients is based on the presence of
symptoms that include gait disturbance, dementia, and
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urinary incontinence [1, 11, 12, 25, 26]. These symptoms
are also present in numerous neurodegenerative disorders,
including Alzheimer’s disease (AD), progressive supra-
nuclear palsy (PSP), and Parkinson’s disease. iNPH is
classically regarded as one of the reversible dementias.
However, the results of shunting are often unsatisfactory,
with greater improvement encountered in early disease and
when memory deficit is only mild or absent [27].
With careful diagnostic evaluation, positive outcome
after shunt surgery may reach as much as 75-87% [9, 10,
13, 33, 36, 38]. To date, adjunctive tests for confirming the
diagnosis of iNPH are not unavailable. Cerebrospinal fluid
(CSF)-based diagnosis of AD includes the measurement of
β-amyloid 1-42 (Aβ1-42) and total tau (t-tau) protein levels
[4, 20, 32]. For the diagnosis of mild cognitive impairment
(MCI), AD and frontotemporal lobe degeneration (FTLD),
the CSF biomarkers Aβ42, Aβ40, t-tau and phosphorylated
tau (p-tau) have been reported to be most useful [7, 19]. It
has been estimated that the measurement of amyloid β and
p-tau levels in the CSF exhibits greater than 85% sensitivity
in the diagnosis of AD [32].
In a recent study using proteome analysis of CSF in
iNPH patients, we reported a significant increase in the
levels of leucine-rich alpha-2-glycoprotein (LRG) in iNPH
patients compared to a control group [23], suggesting that
LRG may be a useful biomarker for iNPH diagnosis.
LRG was isolated from human serum by Haupt and
Baundner in 1977 [14] and its amino acid sequence was
determined in 1985. The LRG consists of 312 amino acid
residues, 66 of which are leucines. This protein contains
eight repeating consensus sequences, each of which con-
sists of 24 amino acid residues and exhibits a periodic
pattern in the occurrence of leucine, proline, and aspara-
gines. This consensus sequence, termed the leucine-rich
repeat (LRR), has now been found in over 55,000
sequences in the Pfam database of protein alignments [24,
37]. In the serum, it has been reported that LRG could be a
marker of granulocytic differentiation and its expression
was up-regulated during neutrophil differentiation [31].
The human LRG gene localizes to chromosome 19p13.3
and its protein is known to exist in the extracellular space.
LRG is co-expressed with transforming growth factor βI
type II receptor (TGF βR-II)[22] and the LRG amino acid
sequence contains a putative membrane-binding region,
thus suggesting potential binding with TGF βR-II on the
cell surface. LRG is thought to bind to collagen and
fibronectin, and some authors believe that LRG also binds
to TGF-β through collagen [22].
In the current study, we report the establishment of a
novel procedure for simultaneously measuring levels of
LRG and total tau protein [21], a marker of neuronal
degeneration in the CSF. We then compare these levels with
tap test results and successful shunt outcomes.
Materials and methods
Patients and sample collection
This study was conducted over a period of 36months between
January 2006 and December 2008 on consecutive, unselected
admissions to our program for iNPH treatment patients with
clinically suspected iNPH [28, 35]. The iNPH was clinically
diagnosed in these patients according to the standard classic
triad of gait impairment, urinary incontinence and impaired
mental function, supported by ventricular dilatation and
dilatation of Sylvian fissures, and narrowing of sulci and
subarachnoid spaces over the high convexity without
significant cerebral atrophy on CT or MRI. Patients with
secondary NPH (e.g., following meningitis, hemorrhage,
brain tumor, or trauma) were not included in this study. A
tap test involving the removal of 30 ml of CSF with an 18-
gauge lumbar puncture needle was performed in 90 patients
(53 men, 37 women; mean age 73.4 years; range: 57 to
86 years). Tap test evaluation criteria were consistent with
Japanese guidelines for iNPH [17, 18] within 1 week after
removal of CSF, and were deemed positive on any of the
following findings: (1) improvement of any item on the
“Japanese normal pressure hydrocephalus grading scale
revised” (JNPHGS-R)[28] (Table 1), (2) ≥ 10% improve-
ment on the 3-m up-and-go test or (3) ≥ three-point




1 Unstable, but independent gait
2 Walking with one cane
3 Walking with two canes or a walker frame
4 Walking not possible
Dementia
0 Within normal range
1 No apparent dementia but apathetic
2 Socially dependent but independent at home




1 Absent but with pollakisuria or urinary urgency
2 Sometimes at night
3 Sometimes even during the day
4 Frequent
a Established by the Research Committee on Intractable Hydrocephalus,
Ministry of Health and Welfare of Japan, 1996. The grades of gait
disturbance, dementia, and urinary incontinence are added to obtain the
total grade, ranging from 0 to 12. (Mori et al. From Ref. 23)
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improvement on the Mini Mental State Examination
(MMSE)[8]. LRG and total tau protein levels were simulta-
neously measured in tap test CSF samples. Lumbar puncture
was performed in the morning under standard condition. A
10-ml CSF sample was collected and gently mixed to avoid
gradient effects. All CSF samples with>500 erythrocytes/μl
were excluded. All CSF samples were centrifuged to remove
cells and debris, aliquoted, and stored at –80°C pending
biochemical analysis. Total tau was measured by sandwich
ELISA (Innotest hTAU-Ag; Innogenetics, Ghent, Belgium).
[30] Nishimura et al. suggest that the appropriate borderline
should be 200–400 pg/ml because 91.4% of AD cases had a
level of more than 200 pg/ml and 100% of neurological
control group subjects had a level of less than 400 pg/ml.
The tau protein kit recommends a cut-off value of clinical
significance at 200 pg/ml of tau in the CSF, with a sensitivity
and specificity for total tau 0.914 and 0.521, respectively. In
the present study, the cut-off value was set at 200 pg/ml to
rule out neurodegenerative diseases, mainly AD.
The LRG antibody was co-developed with Immuno-
Biological Laboratories Co., Ltd. (IBL©) in order to prepare
a sandwich ELISA kit (Human LRG Assay Kit-IBL).
Informed consent was obtained from families prior to
shunt placement for the 52 patients (33 men, 19 women;
mean age 73.5 years; range 57–86 years) who demonstrated
a positive tap test. Lumboperitoneal shunts (LPS) or
ventriculoperitoneal shunts (VPS) were utilized and adjust-
able valves were used in all patients (Cylindrical Valve with
Prechamber® No.82-3110 for VPS and In-Line Valve with
SIPHONGUARD® No.82-3832 for LPS, ©Codman-Ha-
kim, Johnson & Johnson, Raynham, MA).
We evaluated symptom improvements (gait disturbance,
urinary incontinence) and higher cerebral functions, MMSE
and frontal assessment battery; FAB [6]. Surgical outcome
was evaluated 12 months post-operatively. A shunt responder
(SR) was defined as a≥1-grade improvement on the
JNPHGS-R. MRI follow-up was done 3 months, 6 months,
and 12 months after the shunt. If a patient had not improved
clinically and the ventricular system had not decreased in size
at the re-examination, the shunt was tested by radionuclide
shuntography and was surgically corrected if malfunctioning.
In case of subsequent shunt surgery after shunt replacement
caused by dysfunction, values obtained 12 months after the
latest operation were used as post-operative variables.
The study was approved by the ethics committee of
Juntendo University. All patients included in the study, or
their relatives, gave informed consent to their participation.
Statistical analysis
All statistical analyses in clinical studies were performed
with the Statistical Package of the Social Sciences (SPSS
Version 18.0; Cary, NC, USA).
We calculated the relationship between sensitivity and
specificity for SR vs. SNR by ROC curve analysis. The
“optimum” cut-off value from the ROC curve was the point
at which the sum of sensitivity and specificity was
maximal. These calculated protein cut-off values were also
used to distinguish SR from the SNR, which were the
neurodegenerative type of diseases and other dementia
conditions.
The t test was used to investigate differences in
demographics and levels of tau, and LRG in the CSF
between the two pathologic groups. The difference between
the pre- and post-operative values was calculated for each
index, and the mean of the differences was calculated as an
overall result after shunt surgery. Patients showing mean of
difference>0.05 were considered improved, which corre-
sponded to the clinical impression in each case. A p value<
0.01 was considered significant.
Preparation of the human LRG assay Kit-IBL
A sandwich ELISA assay was developed to measure CSF,
serum/plasma, and urinary LRG levels. A key feature of this
portion of the study was the development of specific
antibodies directed against LRG. We produced a human
LRG (329) antibody directed against an amino acid sequence
in the LRG C-terminus (peptide amino acid sequence:
AGPEAVKGQTLLAVAKSQ) and a human LRG (162)
antibody directed against an amino acid sequence located
within close proximity to the N-terminus (peptide amino acid
sequence: GLKALGHLD LSGNRLRKL). Each antigenic
site was found to be involved in maleimide-activated peptide
synthesis with binding to bovine serum thyroglobulin. The
antigen (100 μg) was then mixed with Freund’s complete
adjuvant and was used to immunize rabbits both subcutane-
ously and intradermally. For booster immunization, the
antigen (100 μg) and Freund’s incomplete adjuvant were
both injected subcutaneously and intradermally in eight doses
at 2-week intervals. The antiserum obtained by immunization
was purified on an antigen affinity column prepared by
binding the antigen peptide to Activated Thiol Sepharose 4B
(GE Healthcare). After adsorption with D-PBS buffer (pH
7.4), antibodies were eluted using 0.2 M glycine buffer (pH
2.5). This procedure provided a highly specific polyclonal
antibody.
Measurement of LRG levels using the human LRG assay
Kit-IBL
The sandwich ELISA assay was developed using the
human LRG (162) and LRG (329) antibodies. The human
LRG (162) antibody was diluted in 0.1 M carbonate buffer
(2 μg/100 μl/well), immobilized on ELISA plates and
blocked in BSA solution. A human LRG reference standard
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and the samples (100 μl/well) were added and the trap-
precoated plates were covered with plate lids and incubated
overnight at 4°C to select for human LRG in solution. The
samples were repeatedly washed in PBS containing 0.05%
Tween 20 and then incubated with the horseradish
peroxidase (HRP)-conjugated Fab fragment of the human
LRG (329) antibody (100 μl/well) at 37°C for 30 min. The
labeled Fab fragment is known to bind HRP by the
maleimide method and was purified by gel filtration. The
samples were then washed in PBS containing 0.05% Tween
20 and the HRP color substrate tetra methyl benzidine
(TMB, 100 μl/well) was added. The color reaction was then
quenched with 1 N sulfuric acid and measured at 450 nm
by absorption [i Mark™ Microplate Reader (Bio-Red©)].
Assay values were calculated using a calibration curve
that had been prepared in advance using a reference product
containing a known LRG concentration.
Results
Total LRG and tau levels in CSF samples obtained from
52 patients who underwent shunt placement were
compared between the shunt responder (SR) group,
which demonstrated improved symptoms following shunt
placement, and the shunt nonresponder (SNR) group,
which demonstrated no clinical benefit following shunt
placement. LRG levels were found to be significantly
higher in the SR group (96.8±44.6 ng/ml [mean±SD])
than in the SNR group (29.2±35.1 ng/ml; p<0.01)
(Fig. 1a). Tau protein levels in the CSF did not differ
significantly between the SR group (167.4±105.4 pg/ml)
and the SNR group (264.9±209.5 pg/ml; p>0.05)
(Fig. 1b).
Scatter plots were prepared for LRG and tau values in all
90 patients, with LRG on the vertical axis and tau on the
horizontal axis (Fig. 2a). As can be observed, many
negative tap test patients demonstrated high tau levels,
irrespective of whether low or high LRG levels were
recorded. A comparison of the tau protein levels identified
in the tap test-positive and -negative groups for all 90
patients showed a significant difference between the
positive (186.8±133.3 pg/ml) and negative group (331.5±
277.6 pg/ml; p<0.05). In other words, the determination of
CSF tau protein levels could potentially play an adjunctive
role in the CSF diagnosis of iNPH using LRG levels.
Subsequently, patients were classified into groups based on
their LRG and tau protein levels, and their symptom
improvement was assessed by the tap test and shunt
placement.
The sensitivity and specificity for LRG in CSF for
differentiation of SR from SNR were determined by ROC
curve analysis (Fig. 3). The optimum cut-off was found at
67 ng/ml. ROC curve analysis with area under the curve
(AUC) and SE calculated, 0.792 and 0.078, respectively.
The sensitivity and specificity for LRG are 0.816 and
0.786, respectively.
Four groups were classified based on these cut-off values
and were termed group A (LRG≥67 ng/ml, tau<200 pg/
ml), group B (LRG≥67 ng/ml, tau≥200 pg/ml), group C
(LRG<67 ng/ml, tau<200 pg/ml) and group D (LRG<
67 ng/ml, tau≥200 pg/ml) (Table 2).
The positive tap test results for each group were: group A—
31 of 34 patients (91.2%); group B—15 of 21 patients
(71.4%); group C—15 of 24 patients (62.5%); and
group D—6 of 11 patients (54.2%) (Table 3). We also
evaluated outcome results in the 52 patients who under-
went shunt placement in terms of SR or SNR. In the group
Fig. 1 SR shunt responder, SNR shunt nonresponder. Levels of CSF
LRG (A), tau protein (B) ratio in studied groups. Each blue circle
represents shunt responders and red triangles represent the shunt
nonresponder individual. Horizontal lines indicate median values. a
Correlation between LRG and SR and SNR. LRG levels were found
to be significantly higher in the SR group (96.8±44.6 ng/ml [mean±
SD]) than the SNR group (29.2±35.1 ng/ml; **p<0.01). b Correlation
between tau and SR and SNR. Tau protein levels in the CSF did not
significantly differ between the SR group (167.4±105.4 pg/ml) and
the SNR group (264.9±209.5 pg/ml; p>0.05)
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A—22 of 22 patients were SR (100%), in group B—ten of
11 patients were SR (90.9%), in group C—six of 13
patients were SR (46.2%) and in group D—two of six
patients were SR (33.3%) (Table 3).
MMSE and FAB tests were performed prior to and
12 months following shunt placement to evaluate the
improvement in dementia symptoms. In group A, the
mean MMSE and FAB scores at baseline and 12 months
markedly improved from 22.05 to 25.65 (±0.96) and
11.38 (±0.68) to 13.08 (±0.57), respectively. In group B,
the mean MMSE score improved from 17.62 (±2.03) to
21.62 (±1.96) and the FAB improved from 9.25 (±1.15)
to 10.5 (±1.59), but did not improve beyond the score
limits of dementia. In group C, the mean MMSE score
improved from 22.06 (±1.25) to 24.29 (±1.23) and the
FAB score improved slightly from 12.0 (±0.72) to 12.87
(±0.72). In group D, there was almost no improvement,
MMSE score improved from 17.25 (±4.55) to 17.75
(±4.50) and the FAB improved from 11.33 (±1.86) to
12.33 (±1.20) (Table 4).
Discussion
In the brain of AD patients, specific structures such as
senile plaques and neurofibrillary tangles (NFT) are often
seen [34]. NFT comprise structures called paired helical
filaments (PHF), and the main components are abnormal
phosphate compounds of human tau, a cytoskeleton-related
protein in neurons [15, 16]. In general, human tau is mostly
absent from CSF. However, neuron destruction in neurode-
generative diseases such as AD releases human tau into the
CSF [29]. Human tau levels are thus an indicator of nerve
degeneration, and can be used to rule out psychiatric
disorders unaccompanied by nerve degeneration, such as
dementia and depression. Due to ethical considerations,
shunt surgery was not performed on patients with a
negative tap test (i.e., patients in whom symptoms did not
improve by the tap test, an established diagnostic test).
Diagnostic sensitivity and specificity in the present study
were thus obtained only from a group of patients with a
positive tap test. The assessment criterion for the tap test
was a reduction of≥10% in walk time after tapping.
However, with this test, walk time can shorten because
subjects are instructed to walk in a charge-like manner, and
Fig. 3 ROC curve analysis for LRG in CSF for differentiation of SR
from SNR. ROC curve analysis with area under the curve (AUC) and
SE calculated using Statistical Package for the Social Sciences
(SPSS). The cut-off is given for sensitivity+specificity maximized
for SR vs. SNR. The optimum cut-off was 67 ng/ml for LRG(□). AUC
and SE are 0.792 and 0.078, respectively
Fig. 2 LRG and total tau protein levels in tap tests 90 cases. a Scatter
plot of the CSF LRG and total tau protein levels in 90 patients who
underwent tap tests. Each white circle represents tap test-positive
patients and the yellow square represents tap test-negative patients.
The tau protein kit used in the present study (Innotest hTAU-Ag;
Innogenetics) recommends the cut-off value for clinical manifestation
at 200 pg/ml of tau in the CSF (the solid line). b Scatter plot of the
CSF LRG and total tau protein levels in 52 patients who underwent
shunt replacement. Each white circle represents shunt responders, and
the red triangle represents the shunt nonresponder individual. ROC
curve analysis indicated that the optimum cut-offs (solid line) for SR
vs. SNR was 67 ng/ml for LRG
Table 2 Patient groups according to LRG and TAU levels
Group TAU<200 pg/ml TAU≥200 pg/ml
LRG≥67 ng/ml A B
LRG<67 ng/ml C D
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the cue effect [2, 3] can make patients consciously improve
their time, resulting in numerous false-positive cases. As far
as the diagnostic value of a positive tap test is concerned,
making the definition stricter by using the modified Rankin
scale [5] lowers the sensitivity, but increases the specificity.
The diagnostic standards for the tap test in the present study
were not very strict.
In our study, levels of LRG≥67 ng/ml and tau<200 pg/ml;
group A were associated with increased symptom improve-
ment rates following shunt placement. The higher diagnostic
rate obtained using our procedure, which requires only small
amounts of CSF, suggests that this method may be useful for
diagnosis in patients with lumbar spine degeneration or
scoliosis, where lumbar puncture is often difficult, and the
inconveniences of the tap test or lumbar drainage can be
avoided.
In addition, the findings outlined in our study may also
prove useful for predicting the optimal time for shunt
surgery in iNPH patients. Among the patients that demon-
strated high LRG levels (≥ 67 ng/ml) in the CSF, those that
also had a negative tap test tended to demonstrate high tau
protein levels (tau≥200 pg/ml). In group A (low tau levels;
tau<200 pg/ml), only three of 34 patients also had a
negative tap test. Of the 22 who were positive and received
shunt placement, all 22 showed improvement in their
symptoms. In group B (high tau levels), six of the 21
patients had a negative tap test. Of those who were positive
and had shunt placement, only one patient failed to
demonstrate improvement. In other words, even when
LRG levels in CSF are high, the SNR rate remains low if
tau protein levels are also high.
It is well established that the tau protein is a marker for
neuronal cell death [29]. In group B (LRG≥67 ng/ml, tau≥
200 pg/ml), this indicated either a more advanced iNPH
with irreversible neurologic symptoms or co-existing
neurodegenerative disorders like a AD. Based on our
findings, the prognosis for symptom improvement follow-
ing shunt placement is greater in the early stages of iNPH
before severe neuronal loss occurs, making the perspective
for improvement of symptoms better in group A, where
CSF tau protein levels were less than 200 pg/ml. In group
D, (LRG<67 ng/ml, tau≥200 pg/ml), six patients achieved
a positive tap test, although four patients (66.6%) demon-
strated no symptomatic improvement after shunt placement.
Thus, in group D, where the tap test false-positive rate was
high, progression to neurodegenerative disease is likely and
shunt placement should not be considered beneficial.
Conclusions
In conclusion, LRG levels in the CSF are a potential
biomarker for the diagnosis of iNPH. The combination of a
tap test, excluding a false-positive tap test, and the
measurement of LRG and tau protein levels in the CSF
may accurately predict a group of iNPH patients in whom
shunt placement is likely to improve gait disturbance and
dementia.
Table 3 Evaluation of tap test and shunt response by group









Tap test-positive (n=90) 31/34 (91.2%) 15/21 (71.4%) 15/24 (62.5%) 6/11 (54.2%)
Shunt responder (n=52) 22/22 (100%) 10/11 (90.9%) 6/13 (46.2%) 2/6 (33%)
Group A Group B Group C Group D
MMSE pre (±SE ) 22.05 (±0.96) 17.62 (±2.03) 22.06 (±1.25) 17.25 (±4.55)
12 months after (±SE ) 25.65 (±0.85) 21.62 (±1.96) 24.29 (±1.23) 17.75 (±4.50)
Mean of difference (±SE) 3.6 (±0.76) 4.0 (±1.25) 2.23 (±0.55) 0.5 (±0.87)
CC 0.656 0.806 0.905 0.982
p value ** ** **
FAB pre (±SE ) 11.38 (±0.68) 9.25 (±1.15) 12.0 (±0.72) 11.33 (±1.86)
12 months after (±SE ) 13.08 (±0.57) 10.5 (±1.59) 12.87 (±0.72) 12.33 (±1.20)
post - pre mean (±SE ) 1.69 (±0.57) 1.25 (±0.86) 0.87 (±0.41) 1.0 (±2.0)
CC 0.6 0.852 0.836 0.573
p value *
Table 4 Cognitive outcomes
(52 patients with shunt
placement)
MMSE mini mental state
examination, FAB frontal
association battery
SE standard error, CC
correlation coefficient
P value; p<0.05*, p<0.01**
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Comments
This paper deals with an intriguing and certainly clinically
relevant topic: the possibility of predicting shunting outcome in
iNPH patients, using a combination of positive TT and CSF levels
of LRG and tau proteins. The combination of such biomarkers,
based on a robust cut-off, clearly clustered four groups with
specific cognitive outcome as measured by MMSE and FAB
changes, 12 months after shunting. The statistical analysis is well
conducted and the results are sound. More investigational work is
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